Literature DB >> 3606280

Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics.

S H Kubo, B A Walter, D H John, M Clark, R J Cody.   

Abstract

To characterize the incidence and severity of liver function abnormalities in patients with congestive heart failure, we analyzed systemic hemodynamics and biochemical profiles in 133 patients with stable chronic congestive heart failure, secondary to a dilated cardiomyopathy. The patients were divided into three groups, based on the severity of the reduction in cardiac index (CI). The mean values of all liver function tests in groups 1 (n = 43; CI greater than or equal to 2.0 L/min/m2) and 2 (n = 48; CI greater than 1.5 and less than 2.0 L/min/m2) were essentially normal, except for minimally elevated alkaline phosphatase levels and slightly decreased albumin levels in both groups, and slight increases in levels of gamma-glutamyl transpeptidase and total bilirubin in group 2. In contrast, group 3 patients (n = 42; CI less than or equal to 1.5 L/min/m2) had the most severe heart failure, as assessed by the lowest CI and highest cardiac filling pressures, and significantly higher levels of aspartate aminotransferase (65 +/- 82 U/L), alanine aminotransferase (77 +/- 102 U/L), lactate dehydrogenase (282 +/- 91 U/L), and total bilirubin (29 +/- 14 mumol/L [1.7 +/- 0.8 mg/dL]). The percentage of patients in group 3 with these abnormalities ranged between 27% and 80%. Although linear regression analysis showed that the elevations in right atrial and pulmonary wedge pressures, and the decreases in CI, were significantly correlated with liver function abnormalities, the correlation coefficients were small. Thus, liver function abnormalities remain common in patients with congestive heart failure but are generally small in magnitude and not associated with clinically apparent hepatic disease. It is likely that reduced forward flow and passive backward congestion are both contributing factors in the pathogenesis of these biochemical abnormalities, although nonhemodynamic factors may also be important.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606280

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  31 in total

1.  Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation.

Authors:  Michael J Toth; Martin M LeWinter; Philip A Ades; Dwight E Matthews
Journal:  Clin Sci (Lond)       Date:  2010-08-17       Impact factor: 6.124

2.  Liver complications in patients with congestive heart failure.

Authors:  Cosmas C Giallourakis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Short-term changes in liver tests predict long-term mortality.

Authors:  Eliana Saffouri; Eugénie S Lim; Susan W Kim; Paul Hakendorf; Campbell H Thompson
Journal:  Frontline Gastroenterol       Date:  2016-03-08

5.  The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure.

Authors:  Tetsuya Takahashi; Tetsu Watanabe; Tetsuro Shishido; Ken Watanabe; Takayuki Sugai; Taku Toshima; Daisuke Kinoshita; Miyuki Yokoyama; Harutoshi Tamura; Satoshi Nishiyama; Takanori Arimoto; Hiroki Takahashi; Tamon Yamanaka; Takuya Miyamoto; Isao Kubota
Journal:  Heart Vessels       Date:  2017-12-29       Impact factor: 2.037

6.  Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings.

Authors:  Eric R Fenstad; Bogdan Dzyubak; Jae K Oh; Eric E Williamson; James F Glockner; Phillip M Young; Nandan S Anavekar; Michael D Leise; Richard L Ehman; Philip A Araoz; Sudhakar K Venkatesh
Journal:  J Magn Reson Imaging       Date:  2015-12-21       Impact factor: 4.813

7.  Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction.

Authors:  Aalap Chokshi; Faisal H Cheema; Kenneth J Schaefle; Jeffrey Jiang; Elias Collado; Khurram Shahzad; Tuba Khawaja; Maryjane Farr; Hiroo Takayama; Yoshifumi Naka; Donna M Mancini; P Christian Schulze
Journal:  J Heart Lung Transplant       Date:  2012-03-27       Impact factor: 10.247

8.  Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension.

Authors:  Yasuko Takeda; Yutaka Takeda; Shigehiro Tomimoto; Tomomitsu Tani; Hitomi Narita; Genjiro Kimura
Journal:  BMC Pulm Med       Date:  2010-04-22       Impact factor: 3.317

Review 9.  Physiological changes due to age. Implications for drug therapy of congestive heart failure.

Authors:  R J Cody
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

10.  Prediction of outcome in patients with liver dysfunction after left ventricular assist device implantation.

Authors:  Hiroyuki Nishi; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Satsuki Fukushima; Daisuke Yoshioka; Tetsuya Saito; Shunsuke Saito; Taichi Sakaguchi; Takayoshi Ueno; Toru Kuratani; Yoshiki Sawa
Journal:  J Artif Organs       Date:  2013-08-29       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.